

**SPI-M-O**

# **Medium-Term Projections**

**8<sup>th</sup> December 2021**

# SPI-M-O Medium-term Projections

- **These projections are not forecasts or predictions. They represent a scenario in which the trajectory of the epidemic continues to follow the trends that were seen in the data available to 6<sup>th</sup> December.** The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy and behavioural changes made in the two to three weeks prior to 6<sup>th</sup> December.
- **These projections cannot reflect the current rapid increase of the Omicron variant and its potential impact on the trajectory of the epidemic.** Sustained community transmission of a variant with increased transmissibility relative to Delta, the current dominant strain in the UK, and/or immune escape properties would significantly alter the medium term trajectory of the epidemic.
- **The projections do not include the effects of any future policy or behavioural changes.** The effect of school opening and closing have been included.
- The course of the epidemic has oscillated in several nations and regions over recent weeks. Producing reliable projections is challenging when the epidemic is fluctuating and trends in different data streams conflict.
- **The projections include the impact of vaccines given over the next two weeks.** This has been based on a rollout scenario provided by Cabinet Office for modelling purposes. The rollout scenario assumes doses are administered according to [JCVI's advice](#). It will take time for the continued rollout of doses to impact the epidemic, given lags between vaccination and protection, and between infection and hospital admission.
- Modelling groups have used their expert judgement and evidence from the [UK Health Security Agency](#) and other published efficacy studies when making assumptions about vaccine effectiveness. A table summarising these assumptions is available in the annex.
- Not all modelling groups produce projections for both hospitalisations and deaths, so there will be some differences between the models included in the combined projections for each metric.

## Metrics:

- **New hospitalisations per day:** Number of individuals admitted with COVID-19 and inpatients newly diagnosed with COVID-19. Data definitions differ slightly across all four nations.
- **New deaths per day (by date of death):** The number of COVID-19 deaths within 28 days of a positive test. Data definitions differ slightly across all four nations.

# Modelled projections based on trends to 6<sup>th</sup> December 2021


## New hospital admissions per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks, nor the potential impact of the Omicron variant. These are not forecasts or predictions.


### Key

- Real data
- Expected to Increase
- Projection Midpoint
- High and low estimates 5<sup>th</sup> to 95<sup>th</sup> percentile
- High and low estimates 25<sup>th</sup> to 75<sup>th</sup> percentile
- Models


### ENGLAND




### WALES



### SCOTLAND



### NORTHERN IRELAND



The fan charts show the **90% credible interval and interquartile range** of the combined projections based on current trends.

These projections cannot reflect the current rapid increase of the Omicron variant and its potential impact on the trajectory of the epidemic. Sustained community transmission of a variant with increased transmissibility relative to Delta, the current dominant strain in the UK, and/or immune escape properties would significantly alter the medium term trajectory of the epidemic.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 6<sup>th</sup> December. **The projections do not include the effects of any future policy or behavioural changes.**

These projections include the potential impact of vaccines to be given over the next two weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes. It will take time for the continued rollout of doses to impact the epidemic, given lags between vaccination and protection, and between infection and hospital admission.

#### Data notes:

England: Number of patients admitted with confirmed COVID-19 and the number of inpatients diagnosed with COVID-19 in the past 24 hours. Taken from NHSE COVID-19 Situation reports.

Wales: Number of patients admitted with confirmed COVID-19 and inpatients diagnosed with COVID-19. Provided by Public Health Wales.

Scotland: Number of patients who tested positive for COVID-19 in the 14 days prior to admission, on the day of admission, or during their stay in hospital. Readmissions within 14 days of a positive test are excluded. Provided by Public Health Scotland.

Northern Ireland: Number of patients admitted with confirmed COVID-19 and inpatients diagnosed with COVID-19. Provided by Health and Social Care Northern Ireland.

# Modelled projections based on trends to 6<sup>th</sup> December 2021


## New hospital admissions per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks, nor the potential impact of the Omicron variant. These are not forecasts or predictions.


### Key

- Real data
- Expected to Increase
- Projection Midpoint
- High and low estimates 5<sup>th</sup> to 95<sup>th</sup> percentile
- High and low estimates 25<sup>th</sup> to 75<sup>th</sup> percentile
- Models


EAST OF ENGLAND




LONDON




MIDLANDS




NORTH EAST AND YORKSHIRE




NORTH WEST



SOUTH EAST



SOUTH WEST



The fan charts show the **90% credible interval and interquartile range** of the combined projections based on current trends.

These projections cannot reflect the current rapid increase of the Omicron variant and its potential impact on the trajectory of the epidemic. Sustained community transmission of a variant with increased transmissibility relative to Delta, the current dominant strain in the UK, and/or immune escape properties would significantly alter the medium term trajectory of the epidemic.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 6<sup>th</sup> December. The projections do not include the effects of any future policy or behavioural changes.

These projections include the potential impact of vaccines to be given over the next two weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes. It will take time for the continued rollout of doses to impact the epidemic, given lags between vaccination and protection, and between infection and hospital admission.

### Data notes:

England: Number of patients admitted with confirmed COVID-19 and the number of inpatients diagnosed with COVID-19 in the past 24 hours. The past data is taken from the NHS England COVID-19 Sitreps.

# Modelled projections based on trends to 6<sup>th</sup> December 2021


## New deaths per day

**These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks, nor the potential impact of the Omicron variant. These are not forecasts or predictions.**


### Key

- • Real data
- • Expected to Increase
- Projection Midpoint
- High and low estimates 5<sup>th</sup> to 95<sup>th</sup> percentile
- High and low estimates 25<sup>th</sup> to 75<sup>th</sup> percentile
- Models

### ENGLAND



### SCOTLAND



The fan charts show the **90% credible interval and interquartile range** of the combined projections based on current trends.

**These projections cannot reflect the current rapid increase of the Omicron variant and its potential impact on the trajectory of the epidemic.** Sustained community transmission of a variant with increased transmissibility relative to Delta, the current dominant strain in the UK, and/or immune escape properties would significantly alter the medium term trajectory of the epidemic.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 6<sup>th</sup> December. **The projections do not include the effects of any future policy or behavioural changes.**

**These projections include the potential impact of vaccines to be given over the next two weeks.** This has been based on a rollout scenario provided by Cabinet Office for modelling purposes. It will take time for the continued rollout of doses to impact the epidemic, given lags between vaccination and protection, and between infection and hospital admission.

**Due to an insufficient number of projections, SPI-M-O has been unable to produce consensus projections for the number of deaths in Wales and Northern Ireland this week.**

### Data Notes:

The number of COVID-19 deaths (by date of death) within 28 days of a positive test. The past data for England is taken from the PHE line list of deaths. The past data for Scotland, Wales, and Northern Ireland is taken from the Coronavirus (COVID-19) in the UK dashboard on Gov.uk.








# Modelled projections based on trends to 6<sup>th</sup> December 2021

## New deaths per day

These projections are based on current trends and will not fully reflect the impact of policy or behavioural changes over the past two to three weeks, nor the potential impact of the Omicron variant. These are not forecasts or predictions.

### Key

- • Real data
- • Expected to Increase
- Projection Midpoint
- High and low estimates 5<sup>th</sup> to 95<sup>th</sup> percentile
- High and low estimates 25<sup>th</sup> to 75<sup>th</sup> percentile
- Models



The fan charts show the **90% credible interval and interquartile range** of the combined projections based on current trends.

These projections cannot reflect the current rapid increase of the Omicron variant and its potential impact on the trajectory of the epidemic. Sustained community transmission of a variant with increased transmissibility relative to Delta, the current dominant strain in the UK, and/or immune escape properties would significantly alter the medium term trajectory of the epidemic.

The delay between infection, developing symptoms, the need for hospital care, and death means they cannot fully reflect the impact of policy or behavioural changes in the two to three weeks prior to 6<sup>th</sup> December. The projections do not include the effects of any future policy or behavioural changes.

These projections include the potential impact of vaccines to be given over the next two weeks. This has been based on a rollout scenario provided by Cabinet Office for modelling purposes. It will take time for the continued rollout of doses to impact the epidemic, given lags between vaccination and protection, and between infection and hospital admission.

**Data Notes:**  
 The number of COVID-19 deaths (by date of death) within 28 days of a positive test.  
 The past data for England is taken from the PHE line list of deaths.

# Annex: SPI-M-O Vaccine Effectiveness Assumptions

The LSHTM EpiNow model and Edinburgh WSS model have also been included in the combined projections. The LSHTM EpiNow model projects forward based on the recent trends in the data and doesn't explicitly include the impact of vaccination. However, the protection provided by vaccinations given to date will be reflected in the data and therefore implicitly included in the projections produced by the model. The Edinburgh WSS model does not include any fixed assumptions regarding vaccine efficacy. Instead, the model fits to data from October 2020 to describe the effectiveness of vaccinations at reducing the risk of hospitalisation and death only. These vaccine efficacy estimates are then used when projecting forwards in time.

		Pfizer BioNTech			Oxford-AstraZeneca		Moderna		
		1 Dose	2 Doses	Booster [5]	1 Dose	2 Doses	1 Dose	2 Doses	Booster [5]
<b>Reduction in risk of infection [1]</b>	Manchester [2,3]	75%	75%	75%	75%	75%	75%	75%	75%
	Warwick [2]	55%	85%	92%	45%	70%	55%	85%	92%
	PHE/Cambridge [2]	31%	80%	80%	31%	65%	31%	80%	80%
	Scottish Government [2]	55%	75%	-	40%	65%	73%	83%	-
<b>Reduction in risk of onward transmission, in addition to reduction from lower infection risk [1]</b>	Manchester [2,3,4]	-	-	-	-	-	-	-	-
	Warwick [2]	30%	30%	45%	30%	30%	30%	30%	45%
	PHE/Cambridge [2,4]	-	-	-	-	-	-	-	-
	Scottish Government [2]	29%	40%	-	37%	44%	27%	38%	-
<b>Reduction in risk of hospitalisation [1]</b>	Manchester [2,3]	75%	75%	75%	75%	75%	75%	75%	75%
	Warwick [2]	80%	95%	95%	80%	95%	80%	95%	95%
	PHE/Cambridge [2]	78%	97%	97%	78%	97%	78%	97%	97%
	Scottish Government [2]	80%	95%	-	80%	95%	80%	95%	-
<b>Reduction in risk of death [1]</b>	Manchester [2,3]	75%	75%	75%	75%	75%	75%	75%	75%
	Warwick [2]	80%	98%	98%	80%	98%	80%	98%	98%
	PHE/Cambridge [2]	78%	97%	97%	78%	93%	78%	97%	97%
	Scottish Government [2]	80%	95%	-	80%	95%	80%	95%	-

[1] The assumed delay between vaccination and protection varies between 10 and 21 days for dose 1 and between 7 and 21 days for dose 2 across the modelling groups.

[2] Warwick's model considers a range of scenarios for the partial waning of vaccine effectiveness. The results from these scenarios are then combined to form their projection. The Manchester, PHE/Cambridge and Scottish Government models do not currently include any assumptions for waning of immunity.

[3] Manchester's model does not split vaccine effectiveness by vaccine type or different doses.

[4] The Manchester and PHE/ Cambridge models do not include a reduction in the risk of onwards transmission after receiving either vaccine.

[5] It is assumed that the booster doses administered will be either the Pfizer BioNTech or Moderna vaccines, as per advice from [JCVI](#).